Stories by Rob Garver

A recently exposed case of the agency's handling of drugs that reached the market in spite of fraudulent studies is no anomaly. The agency's response mirrors how it handled an earlier instance of scientific misconduct at another contract research organization

The FDA in 2011 announced years' worth of studies from a major drug research lab were potentially worthless, but it has not pulled any of the compounds from the market nor identified them